Q3 2026
EPS
$0.09
est $0.09+$0.00
Revenue
$95M
est $92M+3.2%
Software revenue grew 11% organically, the first double-digit quarter in two years, and that is the number that decides whether this turnaround is real.
Loading…
Companies
/Healthcare
Certara Inc
$12.05
▼ $0.13 (−1.07%) today
Markets closed · 11:28am ET
CERT at a Glance
Valuation
- Market cap
- $1.8B
Profitability
- Revenue (TTM)
- $412.0M
- Profit margin
- -15.6%
- EPS (TTM)
- $-0.18
Price
- 52-week range
- $4 – $13
- Street target
- $9.17
Headquartered in Radnor, PA Fiscal year ends December NASDAQ: CERT certara.com
About Certara
Certara, Inc. (Nasdaq: CERT) provides biosimulation software, technology and services for model-informed drug discovery and development. Its customers include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
The company reports two revenue streams:
- **Software:** biosimulation software licenses.
- **Services:** consulting and modeling services for drug developers.
In May 2026 Certara divested its Regulatory and Medical Writing business, which is now reported as discontinued operations. This leaves the company focused on biosimulation software and related services. It recently added Grant Peterson, a former DocuSign CTO, as Chief Product Officer to accelerate product growth. Updated
Frequently Asked Questions
What does Certara do?
Certara, Inc. (Nasdaq: CERT) provides biosimulation software, technology and services for model-informed drug discovery and development. Its customers include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
What is the CERT stock price target?
The Wall Street consensus 12-month price target for CERT is $9.17.